Enyo Pharma SAS of France has secured €22 million in a Series A funding round to accelerate development of its lead treatment for hepatitis B virus (HBV) infection which targets interactions in the cell that enable the virus to replicate. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
